KR102520348B1 - 페길화 생활성 펩타이드 및 그의 용도 - Google Patents

페길화 생활성 펩타이드 및 그의 용도 Download PDF

Info

Publication number
KR102520348B1
KR102520348B1 KR1020187033365A KR20187033365A KR102520348B1 KR 102520348 B1 KR102520348 B1 KR 102520348B1 KR 1020187033365 A KR1020187033365 A KR 1020187033365A KR 20187033365 A KR20187033365 A KR 20187033365A KR 102520348 B1 KR102520348 B1 KR 102520348B1
Authority
KR
South Korea
Prior art keywords
ghrh
peg
xaa
salt
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033365A
Other languages
English (en)
Korean (ko)
Other versions
KR20180135016A (ko
Inventor
크리쉬나 지. 페리
Original Assignee
그리폰 파마수티컬스 인터내셔널 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그리폰 파마수티컬스 인터내셔널 에스에이 filed Critical 그리폰 파마수티컬스 인터내셔널 에스에이
Publication of KR20180135016A publication Critical patent/KR20180135016A/ko
Application granted granted Critical
Publication of KR102520348B1 publication Critical patent/KR102520348B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187033365A 2016-04-19 2017-04-18 페길화 생활성 펩타이드 및 그의 용도 Active KR102520348B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (2)

Publication Number Publication Date
KR20180135016A KR20180135016A (ko) 2018-12-19
KR102520348B1 true KR102520348B1 (ko) 2023-04-10

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033365A Active KR102520348B1 (ko) 2016-04-19 2017-04-18 페길화 생활성 펩타이드 및 그의 용도

Country Status (18)

Country Link
US (2) US10918730B2 (cg-RX-API-DMAC7.html)
EP (1) EP3445778B1 (cg-RX-API-DMAC7.html)
JP (1) JP7134093B2 (cg-RX-API-DMAC7.html)
KR (1) KR102520348B1 (cg-RX-API-DMAC7.html)
CN (1) CN109153712B (cg-RX-API-DMAC7.html)
AU (1) AU2017254754B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070929A2 (cg-RX-API-DMAC7.html)
CA (1) CA3021231A1 (cg-RX-API-DMAC7.html)
DK (1) DK3445778T3 (cg-RX-API-DMAC7.html)
ES (1) ES2824781T3 (cg-RX-API-DMAC7.html)
HU (1) HUE052802T2 (cg-RX-API-DMAC7.html)
IL (1) IL262356B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018012716A (cg-RX-API-DMAC7.html)
PL (1) PL3445778T3 (cg-RX-API-DMAC7.html)
PT (1) PT3445778T (cg-RX-API-DMAC7.html)
RU (1) RU2748576C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201808880PA (cg-RX-API-DMAC7.html)
WO (1) WO2017181277A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344B (zh) 2020-10-09 2026-06-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
KR20020047096A (ko) 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews, (2003), vol. 55, no. 10, pages 1279 - 1291

Also Published As

Publication number Publication date
EP3445778A4 (en) 2019-05-01
US20170296628A1 (en) 2017-10-19
PL3445778T3 (pl) 2021-02-22
RU2018140501A (ru) 2020-05-19
US10918730B2 (en) 2021-02-16
RU2748576C2 (ru) 2021-05-27
AU2017254754B2 (en) 2021-02-04
IL262356A (en) 2018-11-29
US20190209699A1 (en) 2019-07-11
US9988428B2 (en) 2018-06-05
EP3445778B1 (en) 2020-07-15
ES2824781T3 (es) 2021-05-13
PT3445778T (pt) 2020-10-15
DK3445778T3 (da) 2020-10-12
EP3445778A1 (en) 2019-02-27
BR112018070929A2 (pt) 2019-02-26
JP7134093B2 (ja) 2022-09-09
IL262356B2 (en) 2023-06-01
CA3021231A1 (en) 2017-10-26
JP2019516675A (ja) 2019-06-20
RU2018140501A3 (cg-RX-API-DMAC7.html) 2020-09-08
CN109153712B (zh) 2022-09-16
SG11201808880PA (en) 2018-11-29
WO2017181277A1 (en) 2017-10-26
KR20180135016A (ko) 2018-12-19
HUE052802T2 (hu) 2021-05-28
CN109153712A (zh) 2019-01-04
AU2017254754A1 (en) 2018-11-01
MX2018012716A (es) 2019-02-11

Similar Documents

Publication Publication Date Title
CN111491658A (zh) 肠促胰岛素类似物及其用途
US20110136733A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
CN114787183A (zh) 肠促胰岛素类似物及其用途
JP2022551153A (ja) 活性ポリペプチド化合物
US11572399B2 (en) Long-acting GIP peptide analogues
EP4658674A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
KR20150005904A (ko) 강력한 작용제 효과를 지닌 신규한 ｇｈ-ｒｈ 유사체
AU2017254754B2 (en) PEGylated bioactive peptides and uses thereof
AU2005224027A1 (en) Y2/Y4 selective receptor agonists for therapeutic interventions
RU2540012C2 (ru) Мотилин-подобное пептидное соединение, обладающее приданной ему трансмукозальной абсорбционной способностью
US8361964B2 (en) Growth hormone releasing factor (GRF) analogs and uses thereof
US12415834B2 (en) GhR-binding peptide and composition comprising same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20190910

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200417

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210831

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220307

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220916

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230406

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230406

End annual number: 3

Start annual number: 1

PG1601 Publication of registration